Genzyme Revenues Up
Genzyme Corp. increased its revenue 7 percent year-over-year in the first quarter of 2011, before being acquired by Sanofi-Aventis.
The company, which is based in Cambridge but has significant operations in MetroWest, had revenues of just over $1 billion for the quarter.
Sales of Myozyme/Lumizyme, which is used to treat the neuromuscular disorder Pompe disease, grew 47 percent to $126.5 million. Sales of the Gaucher disease drug Cerezyme grew 2.6 percent to $183.8 million, although production problems caused European and Japanese patients to miss a dose of the drug. Sales of Fabrazyme, which is used to treat Fabry disease, fell 23 percent to $40.9 million because of ongoing supply problems.
The company's personalized genetic health business grew 11 percent to $436.9 million, and its renal and endocrinology business fell 6.7 percent to $250.7 million, while its biosurgery business increased 12 percent to $153.8 million.
Sanofi Aventis of France completed the acquisition of Genzyme on April 8.
WBJ Web Partners
Most Recent
Most Recent
0 Comments